Cas:866807-27-4 3-Amino-6-chloro-2-pyridinecarboxylic acid manufacturer & supplier

Chemical Name:3-Amino-6-chloro-2-pyridinecarboxylic acid

CAS.NO:866807-27-4

Synonyms:2-Pyridinecarboxylic acid, 3-amino-6-chloro-;3-amino-6-chloro-pyridine-2-carboxylic acid;3-Amino-6-chloro-2-pyridinecarboxylic acid;3-Amino-6-chloropyridine-2-carboxylic acid;3-Amino-6-chloro-2-pyridine carboxylic acid;2-Pyridinecarboxylic acid,3-aMino-6-chloro

Molecular Formula:C₆H₅ClN₂O₂

Molecular Weight:172.569

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:413.6±45.0 °C at 760 mmHg

Density:1.6±0.1 g/cm3

Index of Refraction:1.660

PSA:76.21000

Exact Mass:172.003952

LogP:1.06

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Pyridinecarboxylic acid, 3-amino-6-chloro- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Pyridinecarboxylic acid,3-aMino-6-chloro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Amino-6-chloro-2-pyridinecarboxylic acid Use and application,3-amino-6-chloro-pyridine-2-carboxylic acid technical grade,usp/ep/jp grade.

Related News: If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role. 3-Amino-6-chloro-2-pyridinecarboxylic acid manufacturer This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. 3-Amino-6-chloro-2-pyridinecarboxylic acid supplier At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities. 3-Amino-6-chloro-2-pyridinecarboxylic acid vendor ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 3-Amino-6-chloro-2-pyridinecarboxylic acid factory ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.